LOS ANGELES, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that President and Chief Operating Officer, Elma Hawkins, Ph.D., will present at the Piper Jaffray 26th Annual Healthcare Conference on Wednesday, December 3, 2014, at 4:00 p.m. Eastern. The conference is being held at The New York Palace Hotel, from December 2-3, 2014.
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.lionbio.com.
CONTACT: Investor Relations
The Trout Group
Gitanjali Jain Ogawa
646-378-2949
gogawa@troutgroup.com
Source: Lion Biotechnologies, Inc.
Released December 1, 2014